Announcement PDF Neuren (NEU) – ASX Announcement 8 September 2025 Changes in securities interests of CEO & Managing Director In July 2025 Neuren’s CEO & Managing Director, Jon Pilcher, paid $2.8 million to Neuren to extinguish the loan attached to 1.5 million Loan Funded Shares, which was expiring after 5 years. At that time, he was restricted from selling any shares to fund the loan repayment and taxes, pending Acadia’s Q2 2025 earnings announcement, followed by Neuren’s H1 2025 results announcement on 27 August 2025. As detailed in the attached Change of Director’s Interest Notice, 398,207 shares have now been sold to a small number of institutional investors. The loan repayment and share sale transactions resulted in the following: • • • Neuren’s cash and share capital increased by $2.8 million. The CEO’s quoted shareholding increased from 0.4 million shares to 1.5 million shares, placing him in the top 15 beneficial holders and top 10 registered holders. Neuren’s institutional shareholdings increased by 0.4 million shares. About Neuren Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) and Health Canada for the treatment of Rett syndrome. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren’s second drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome and Angelman syndrome. Contact: investorrelations@neurenpharma.com Jon Pilcher, CEO: +61 438 422 271 ASX Listing Rules information This announcement was authorized to be given to the ASX by the CEO & Managing Director of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 Appendix 3Y Change of Director’s Interest Notice Appendix 3Y Rule 3.19A.2 Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Neuren Pharmaceuticals Limited ARBN: 111 496 130 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Jonathan Pilcher Date of last notice 22 July 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct and Indirect interest Nature of indirect interest (including registered holder) Mrs J L Pilcher (spouse) Date of change 8 September 2025 No. of securities held prior to change Direct interest in 1,500,000 Ordinary shares and indirect interest in 398,207 Ordinary shares Class Ordinary shares Note: Provide details of the circumstances giving rise to the relevant interest. Number acquired Number disposed 398,207 Value/Consideration $20.00 per share Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Direct interest in 1,500,000 Ordinary shares Nature of change On-market crossing Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract Not applicable Nature of interest Not applicable Name of registered holder (if issued securities) Not applicable Date of change Not applicable No. and class of securities to which Not applicable interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Not applicable Interest disposed Not applicable Value/Consideration Not applicable Interest after change Not applicable Note: If consideration is non-cash, provide details and an estimated valuation Part 3 – +Closed period Were the interests in the securities or contracts detailed Not applicable above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade Not applicable to proceed during this period? If prior written clearance was provided, on what date was this Not applicable provided? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011